Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Drug Safety
Erschienen in: Drug Safety 12/2018

01.12.2018 | Review Article

Risks of Opioids in ST-Elevation Myocardial Infarction: A Review

verfasst von: Anne Henrieke Tavenier, Renicus Suffridus Hermanides, Jan Paul Ottervanger, Peter Gerrit Johannes Ter Horst, Elvin Kedhi, Adriaan W. J. van ‘t Hof

Erschienen in: Drug Safety | Ausgabe 12/2018

Einloggen, um Zugang zu erhalten

Abstract

Although opioids are recommended and frequently used in the acute phase of ST-elevation myocardial infarction (STEMI), their use is accompanied by serious side effects. In particular, gastrointestinal adverse effects may disturb absorption of essential oral medication like platelet inhibitors. This may cause suboptimal platelet inhibition and increased risk of acute stent thrombosis. Some clinical studies have already demonstrated these negative results. Alternative strategies to optimize platelet inhibition and pain relief in STEMI are being investigated. Clinicians should become more aware of the potential side effects of opioids in STEMI.
Literatur
1.
Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the Management of Acute Myocardial Infarction in Patients Presenting with ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–77.CrossRef
2.
O’Gara PT, Kushner FG, Ascheim DD, Casey DE, Jr, Chung MK, de Lemos JA, et al. ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;124(4):e362–425.
3.
Parodi G. Editor’s Choice-Chest pain relief in patients with acute myocardial infarction. Eur Heart J Acute Cardiovasc Care. 2016;5(3):277–81.CrossRef
4.
Holzer P. Pharmacology of opioids and their effects on gastrointestinal function. Am J Gastroenterol Suppl. 2014;2:9–16.CrossRef
5.
Brownstein MJ. A brief history of opiates, opioid peptides, and opioid receptors. Proc Natl Acad Sci USA. 1993;90(12):5391–3.CrossRef
6.
Headrick JP, See Hoe LE, Du Toit EF, Peart JN. Opioid receptors and cardioprotection—’opioidergic conditioning’ of the heart. Br J Pharmacol. 2015;172(8):2026–50.CrossRef
7.
Sobanski P, Krajnik M, Shaqura M, Bloch-Boguslawska E, Schafer M, Mousa SA. The presence of mu-, delta-, and kappa-opioid receptors in human heart tissue. Heart Vessels. 2014;29(6):855–63.CrossRef
8.
Tantry US, Bonello L, Aradi D, Price MJ, Jeong YH, Angiolillo DJ, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol. 2013;62(24):2261–73.CrossRef
9.
Kubo S, Kadota K, Ichinohe T, Miyake K, Hyodo Y, Otsuru S, et al. Comparison of long-term outcome after percutaneous coronary intervention for stent thrombosis between early, late, and very late stent thrombosis. Circ J. 2014;78(1):101–9.CrossRef
10.
Claessen BE, Henriques JP, Jaffer FA, Mehran R, Piek JJ, Dangas GD. Stent thrombosis: a clinical perspective. JACC Cardiovasc Interv. 2014;7(10):1081–92.CrossRef
11.
Schultz JE, Gross GJ. Opioids and cardioprotection. Pharmacol Ther. 2001;89(2):123–37.CrossRef
12.
Rentoukas I, Giannopoulos G, Kaoukis A, Kossyvakis C, Raisakis K, Driva M, et al. Cardioprotective role of remote ischemic periconditioning in primary percutaneous coronary intervention: enhancement by opioid action. JACC Cardiovasc Interv. 2010;3(1):49–55.CrossRef
13.
Johnson MW, Mitch WE, Wilcox CS. The cardiovascular actions of morphine and the endogenous opioid peptides. Prog Cardiovasc Dis. 1985;27(6):435–50.CrossRef
14.
Coltart DJ, Malcolm AD. Pharmacological and clinical importance of narcotic antagonists and mixed antagonists–use in cardiology. Br J Clin Pharmacol. 1979;7(Suppl 3):309S–11S.CrossRef
15.
McCarthy CP, Mullins KV, Sidhu SS, Schulman SP, McEvoy JW. The on- and off-target effects of morphine in acute coronary syndrome: a narrative review. Am Heart J. 2016;176:114–21.CrossRef
16.
Herlitz J, Hjalmarson A, Waagstein F. Treatment of pain in acute myocardial infarction. Br Heart J. 1989;61(1):9–13.CrossRef
17.
Kubica J, Adamski P, Ostrowska M, Sikora J, Kubica JM, Sroka WD, et al. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. Eur Heart J. 2016;37(3):245–52.CrossRef
18.
Boyer EW. Management of opioid analgesic overdose. N Engl J Med. 2012;367(2):146–55.CrossRef
19.
Feng XQ, Zhu LL, Zhou Q. Opioid analgesics-related pharmacokinetic drug interactions: from the perspectives of evidence based on randomized controlled trials and clinical risk management. J Pain Res. 2017;24(10):1225–39.CrossRef
20.
Parodi G, Bellandi B, Xanthopoulou I, Capranzano P, Capodanno D, Valenti R, et al. Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ Cardiovasc Interv. 2014;8:e001593.PubMed
21.
Hozumi J, Egi M, Sugita S, Sato T. Dose of intraoperative remifentanil administration is independently associated with increase in the risk of postoperative nausea and vomiting in elective mastectomy under general anesthesia. J Clin Anesth. 2016;34:227–31.CrossRef
22.
Yoo YC, Na S, Jeong JJ, Choi EM, Moon BE, Lee JR. Dose-dependent attenuation by fentanyl on cough during emergence from general anesthesia. Acta Anaesthesiol Scand. 2011;55(10):1215–20.CrossRef
23.
Chen J, Li W, Wang D, Hu X. The effect of remifentanil on cough suppression after endoscopic sinus surgery: a randomized study. Acta Anaesthesiol Scand. 2010;54(10):1197–203.CrossRef
24.
Overholser BR, Foster DR. Opioid pharmacokinetic drug-drug interactions. Am J Manag Care. 2011;17(Suppl. 11):S276–87.PubMed
25.
Johnson TW, Mumford AD, Scott LJ, Mundell S, Butler M, Strange JW, et al. A study of platelet inhibition, using a ‘point of care’ platelet function test, following primary percutaneous coronary intervention for ST-elevation myocardial infarction [PINPOINT-PPCI]. PLoS One. 2015;10(12):e0144984.CrossRef
26.
Xanthopoulou I, Davlouros P, Tsigkas G, Koutsogiannis N, Patsilinakos S, Deftereos S, et al. Factors affecting platelet reactivity 2 hours after P2Y(1)(2) receptor antagonist loading in primary percutaneous coronary intervention for ST-elevation myocardial infarction—impact of pain-to-loading time. Circ J. 2016;80(2):442–9.CrossRef
27.
McEvoy JW, Ibrahim K, Kickler TS, Clarke WA, Hasan RK, Czarny MJ, et al. Effect of intravenous fentanyl on ticagrelor absorption and platelet inhibition among patients undergoing percutaneous coronary intervention: the PACIFY randomized clinical trial (Platelet Aggregation with Ticagrelor Inhibition and Fentanyl). Circulation. 2018;137(3):307–9.CrossRef
28.
Silvain J, Storey RF, Cayla G, Esteve JB, Dillinger JG, Rousseau H, et al. P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction. The PRIVATE-ATLANTIC study. Thromb Haemost. 2016;116(2):369–78.CrossRef
29.
Thomas MR, Morton AC, Hossain R, Chen B, Luo L, Shahari NN, et al. Morphine delays the onset of action of prasugrel in patients with prior history of ST-elevation myocardial infarction. Thromb Haemost. 2016;116(1):96–102.CrossRef
30.
de Waha S, Eitel I, Desch S, Fuernau G, Lurz P, Urban D, et al. Intravenous morphine administration and reperfusion success in ST-elevation myocardial infarction: insights from cardiac magnetic resonance imaging. Clin Res Cardiol. 2015;104(9):727–34.CrossRef
31.
Gwag HB, Park TK, Song YB, Kim EK, Jang WJ, Yang JH, et al. Morphine does not affect myocardial salvage in ST-segment elevation myocardial infarction. PLoS One. 2017;12(1):e0170115.CrossRef
32.
Bellandi B, Zocchi C, Xanthopoulou I, Scudiero F, Valenti R, Migliorini A, et al. Morphine use and myocardial reperfusion in patients with acute myocardial infarction treated with primary PCI. Int J Cardiol. 2016;15(221):567–71.CrossRef
33.
Puymirat E, Lamhaut L, Bonnet N, Aissaoui N, Henry P, Cayla G, et al. Correlates of pre-hospital morphine use in ST-elevation myocardial infarction patients and its association with in-hospital outcomes and long-term mortality: the FAST-MI (French Registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction) programme. Eur Heart J. 2016;37(13):1063–71.CrossRef
34.
Bonin M, Mewton N, Roubille F, Morel O, Cayla G, Angoulvant D, et al. Effect and safety of morphine use in acute anterior ST-segment elevation myocardial infarction. J Am Heart Assoc. 2018;7(4):e006833.CrossRef
35.
Meine TJ, Roe MT, Chen AY, Patel MR, Washam JB, Ohman EM, et al. Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. Am Heart J. 2005;149(6):1043–9.CrossRef
36.
Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med. 2013;368(14):1303–13.CrossRef
37.
Venetsanos D, Sederholm Lawesson S, Swahn E, Alfredsson J. Chewed ticagrelor tablets provide faster platelet inhibition compared to integral tablets: the inhibition of platelet aggregation after administration of three different ticagrelor formulations (IPAAD-Tica) study, a randomised controlled trial. Thromb Res. 2017;149:88–94.CrossRef
38.
Crean B, Finnie C, Crosby A. Evaluation of crushed ticagrelor tablet doses: recovery following crushing and naso-gastric tube passage ex vivo. Drugs R D. 2013;13(2):153–7.CrossRef
39.
Parodi G, Xanthopoulou I, Bellandi B, Gkizas V, Valenti R, Karanikas S, et al. Ticagrelor crushed tablets administration in STEMI patients: the MOJITO study. J Am Coll Cardiol. 2015;65(5):511–2.CrossRef
40.
Rollini F, Franchi F, Hu J, Kureti M, Aggarwal N, Durairaj A, et al. Crushed prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary intervention: the CRUSH Study. J Am Coll Cardiol. 2016;67(17):1994–2004.CrossRef
41.
Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286(8):954–9.CrossRef
42.
Pitt B, Pepine C, Willerson JT. Cyclooxygenase-2 inhibition and cardiovascular events. Circulation. 2002;106(2):167–9.CrossRef
43.
Shau WY, Chen HC, Chen ST, Chou HW, Chang CH, Kuo CW, et al. Risk of new acute myocardial infarction hospitalization associated with use of oral and parenteral non-steroidal anti-inflammation drugs (NSAIDs): a case-crossover study of Taiwan’s National Health Insurance claims database and review of current evidence. BMC Cardiovasc Disord. 2012;12:4-2261-12-4.CrossRef
44.
Cantais A, Schnell D, Vincent F, Hammouda Z, Perinel S, Balichard S, et al. Acetaminophen-induced changes in systemic blood pressure in critically ill patients: results of a multicenter cohort study. Crit Care Med. 2016;44(12):2192–8.CrossRef
45.
Chiam E, Weinberg L, Bailey M, McNicol L, Bellomo R. The haemodynamic effects of intravenous paracetamol (acetaminophen) in healthy volunteers: a double-blind, randomized, triple crossover trial. Br J Clin Pharmacol. 2016;81(4):605–12.CrossRef
Metadaten
Titel
Risks of Opioids in ST-Elevation Myocardial Infarction: A Review
verfasst von
Anne Henrieke Tavenier
Renicus Suffridus Hermanides
Jan Paul Ottervanger
Peter Gerrit Johannes Ter Horst
Elvin Kedhi
Adriaan W. J. van ‘t Hof
Publikationsdatum
01.12.2018
Verlag
Springer International Publishing
Erschienen in
Drug Safety / Ausgabe 12/2018
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI
https://doi.org/10.1007/s40264-018-0710-y

Weitere Artikel der Ausgabe 12/2018

Drug Safety 12/2018 Zur Ausgabe

Correction

Correction to: Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial Experience

Original Research Article

Proton Pump Inhibitor Use and Risk of Developing Alzheimer’s Disease or Vascular Dementia: A Case–Control Analysis

Letter to the Editor

Comment on: “Mixed Approach Retrospective Analyses of Suicide and Suicidal Ideation for Brand Compared with Generic Central Nervous System Drugs”

Letter to the Editor

Authors’ Response to Braillon’s Comment on: “Limited Evidence for Risk Factors for Proarrhythmia and Sudden Cardiac Death in Patients Using Antidepressants: Dutch Consensus on ECG Monitoring”

Letter to the Editor

Authors' Reply to Courtney Suggs and Colleagues’ Comment on: “Mixed Approach Retrospective Analyses of Suicide and Suicidal Ideation for Brand Compared with Generic Central Nervous System Drugs”

Letter to the Editor

Authors’ Reply to Katsuhiro Toda’s Comment on “Proton Pump Inhibitor Use and Risk of Developing Alzheimer’s Disease or Vascular Dementia: A Case-Control Analysis”